Patents by Inventor Adrian Zwick
Adrian Zwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002506Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.Type: ApplicationFiled: June 20, 2023Publication date: January 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Laura CODARRI DEAK, Stefan C. DENGL, Jens FISCHER, Christian KLEIN, Stefan SEEBER, Patrick Alexander Aaron WEBER, Adrian ZWICK
-
Publication number: 20230279109Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.Type: ApplicationFiled: March 20, 2023Publication date: September 7, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20230183349Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.Type: ApplicationFiled: March 3, 2023Publication date: June 15, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Laura CODARRI DEAK, Stefan DENGL, Sebastian FENN, Jens FISCHER, Guy GEORGES, Christian KLEIN, Viktor LEVITSKI, Valeria LIFKE, Oliver PLOETTNER, Stefan SEEBER, Barbara WEISER, Ildiko WUENSCHE, Adrian ZWICK
-
Publication number: 20230143310Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.Type: ApplicationFiled: June 30, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
-
Publication number: 20220363755Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.Type: ApplicationFiled: December 20, 2021Publication date: November 17, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20220259314Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 3, 2021Publication date: August 18, 2022Applicant: Hoffmann-La Roche Inc.Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
-
Publication number: 20220099680Abstract: Herein is reported a heterodimeric fusion polypeptide comprising a first proteinaceous moiety and a second proteinaceous moiety, wherein the first proteinaceous moiety and the second proteinaceous moiety are the first and the second antigen of a bispecific antibody which comprises a first binding site that specifically binds to the first proteinaceous moiety and a second binding site that specifically binds to the second proteinaceous moiety, wherein the first proteinaceous moiety is fused to the N-terminus of a first antibody heavy chain Fc-region polypeptide of the IgG1 subtype, wherein the second proteinaceous moiety is fused to the N-terminus of a second antibody heavy chain Fc-region polypeptide of the IgG1 subtype, wherein the first and the second heavy chain Fc-region polypeptide form a disulfide-linked heterodimer, wherein one or both of the heavy chain Fc-region polypeptides comprise a tag for immobilization to a solid phase at its C-terminus, and wherein the first and the second Fc-region polypeptidType: ApplicationFiled: September 29, 2021Publication date: March 31, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Diana Angela PIPPIG, Tilman SCHLOTHAUER, Stefan SEEBER, Adrian ZWICK
-
Patent number: 11130810Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: GrantFiled: March 27, 2019Date of Patent: September 28, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20200277372Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.Type: ApplicationFiled: October 2, 2019Publication date: September 3, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Laura CODARRI DEAK, Stefan C. DENGL, Jens FISCHER, Christian KLEIN, Stefan SEEBER, Patrick Alexander Aaron WEBER, Adrian Zwick
-
Publication number: 20200108154Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: ApplicationFiled: August 28, 2019Publication date: April 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jen FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
-
Publication number: 20190382489Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.Type: ApplicationFiled: December 18, 2018Publication date: December 19, 2019Applicant: Hoffmann-La Roche Inc.Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
-
Publication number: 20190382480Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.Type: ApplicationFiled: February 6, 2019Publication date: December 19, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20190322748Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: March 27, 2019Publication date: October 24, 2019Applicant: Hoffmann-La Roche Inc.Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
-
Patent number: 10434184Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: GrantFiled: April 27, 2018Date of Patent: October 8, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Sebastian Fenn, Jens Fischer, Thomas Friess, Sabine Imhof-Jung, Ben-Fillippo Krippendorff, Christian Schantz, Tilman Schlothauer, Claudio Sustmann, Barbara Weiser, Adrian Zwick
-
Patent number: 10287352Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: GrantFiled: September 29, 2016Date of Patent: May 14, 2019Assignee: HOFFMAN-LA ROCHE INC.Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20180311371Abstract: The invention provides anti-TPBG antibodies and methods of using the same.Type: ApplicationFiled: April 27, 2018Publication date: November 1, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
-
Publication number: 20180072804Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.Type: ApplicationFiled: April 21, 2017Publication date: March 15, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20170247454Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.Type: ApplicationFiled: September 29, 2016Publication date: August 31, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Laura Codarri Deak, Stefan Dengl, Sebastian Fenn, Jens Fischer, Guy Georges, Christian Klein, Viktor Levitski, Valeria Lifke, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
-
Publication number: 20170114135Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 29, 2016Publication date: April 27, 2017Applicant: Hoffmann-La Roche Inc.Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
-
Publication number: 20160257749Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.Type: ApplicationFiled: November 6, 2015Publication date: September 8, 2016Applicant: HOFFMANN-LA ROCHE, INC.Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick